Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows

Aclaris Therapeutics

06/11/2025 12:07

Overview

Aclaris Q3 revenue beats analyst expectations despite a year-over-year decline

Net loss for Q3 smaller than expected, reflecting better financial performance

Company reports positive Phase 2a trial results for ATI-2138 in atopic dermatitis

Outlook

Aclaris plans Phase 2 trial of ATI-2138 in H1 2026 for new indications

Company expects Phase 1b trials of ATI-052 in asthma and AD in H1 2026

Aclaris expects cash runway to fund operations into H2 2028

Result Drivers

NET LOSS - Net loss was $14.6 million for the third quarter of 2025 compared to $7.6 million for the third quarter of 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$3.30 mln
$1.59 mln (6 Analysts)
Q3 Net Income
Beat
-$14.61 mln
-$15.80 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 67.7% above its November 5 closing price of $2.26

Press Release: ID:nGNX25vlxp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)